Effectiveness and safety of tocilizumab in patients with systemic sclerosis: a propensity score matched controlled observational study of the EUSTAR cohort.
Simon KusterSuzana JordanMuriel ElhaiUlrike HeldKlaus SteigmillerCosimo BruniFabio CacciapagliaSerena VettoriElise SiegertSimona RednicVeronica CodulloPaolo AiroYolanda Braun-MoscoviciNicolas HunzelmannMaria Joao SalvadorValeria RiccieriAna-Maria GheorghiuJuan José Alegre SanchoKatarzyna Romanowska-ProchnickaIvan CastellviIna KötterMarie-Elise TruchetetF J López-LongoPavel I NovikovAlessandro GiolloYuichiro ShiraiLaura BelloliElisabetta ZanattaEric HachullaVanessa SmithChris DentonRuxandra M IonescuTim SchmeiserJoerg H W DistlerArmando GabrielliAnna-Maria Hoffmann-VoldMasataka KuwanaYannick AllanoreOliver Distlernull nullPublished in: RMD open (2022)
Although this large, observational, controlled, real-life EUSTAR study did not show significant effectiveness of tocilizumab on skin and lung fibrosis, the consistency of direction of all predefined endpoints generates hypothesis for potential effectiveness in a broader SSc population.